Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 76Leukemia 43Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Leukemia, Myelomonocytic, Acute 16Leukemia, Monocytic, Acute 16Congenital Abnormalities 16Leukemia, Megakaryoblastic, Acute 14Leukemia, Erythroblastic, Acute 14Myelodysplastic Syndromes 11Leukemia, Promyelocytic, Acute 8Leukemia, Myelomonocytic, Chronic 8Anemia, Refractory, with Excess of Blasts 8Recurrence 6Myeloproliferative Disorders 5Leukemia, Eosinophilic, Acute 5Leukemia, Basophilic, Acute 4Lymphoma 3Leukemia, Myeloid, Chronic-Phase 3Blast Crisis 3Neutropenia 2Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Carcinoma, Hepatocellular 2Thrombocythemia, Essential 1Sarcoma, Synovial 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasms × Idarubicin × Clear all
NCT02834390 2025-03-05

Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Daiichi Sankyo

Phase 1 Completed
7 enrolled 16 charts
Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT01035502 2013-09-27

A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia

Clavis Pharma

Phase 2 Completed
51 enrolled
Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡